Rona Therapeutics Reports NMPA’s IND Acceptance of RN1871 for Hypertension
Shots:
- China’s NMPA has accepted IND application for RN1871 for hypertension, with Rona planning to advance it in P-I trial to assess its safety, PK, & preliminary efficacy in humans
- Preclinical studies have demonstrated AGT suppression & sustained blood pressure control, with reduced dosing frequency of RN1871
- RN1871 is engineered to suppress AGT mRNA expression in the liver, blocking the production of the key precursor protein involved in the Renin-Angiotensin-Aldosterone System (RAAS)
Ref: Prnewswire | Image: Rona Therapeutics
Related News:- HighField Biopharmaceuticals Seeks NMPA’s IND Clearance for HF158K1 & HFK2 to Treat Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
